Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
|Articles|June 14, 2006
Tracked and Traced at Every Stage?
Tracked and Traced at Every Stage?
Advertisement
If you are looking for totally compliant track and trace solutions? Look no further than Domino, the experienced coding partner.
Domino provides a complete range of solutions for variable printing applications offering interoperable coding platforms using laser, ink jet and RFID, with supporting software and connectivity.
They are experts in coding integrity and security solutions across a wide range of global industries with product traceability, using linear and composite codes such as Data Matrix including human readable information, at the core of their service offering.
Due to their unique industry knowledge, ensuring fully compliant solutions, the Integrated Solutions Group provide complete management support encompassing initial system design, migration and implementation strategy, installation, training and maintenance.
Need an industry partner? Choose Domino.
For more details
Advertisement
Related to this article
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Inovalon's Jen Lamppa on why inaccurate self-reported data is clinical trial enrollment's costliest problem — and how RWD fixes it.
Five major pharma stories in one day — Novo's rebrand and AI bets, Bayer's 30-year CKD first, GSK's T-cell engager, and Sanofi's portfolio exit.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
2
Understanding the Latest with MFN Pricing and What It Means to Pharma
3
The Battle to Own the GLP-1 Patient Journey
4
Novo Announces Drug Discovery Collaboration with Anthropic
5